PT1491201E - Metodos de reducao da toxicidade de 5-fluoracil com nucleosidos pirimidicos acilados - Google Patents

Metodos de reducao da toxicidade de 5-fluoracil com nucleosidos pirimidicos acilados

Info

Publication number
PT1491201E
PT1491201E PT04023557T PT04023557T PT1491201E PT 1491201 E PT1491201 E PT 1491201E PT 04023557 T PT04023557 T PT 04023557T PT 04023557 T PT04023557 T PT 04023557T PT 1491201 E PT1491201 E PT 1491201E
Authority
PT
Portugal
Prior art keywords
acillated
pyrimidic
fluoracil
nucleosides
methods
Prior art date
Application number
PT04023557T
Other languages
English (en)
Inventor
Reid W Vonborstel
Michael K Bamat
Original Assignee
Wellstat Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Therapeutics Corp filed Critical Wellstat Therapeutics Corp
Publication of PT1491201E publication Critical patent/PT1491201E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
PT04023557T 1995-06-07 1996-06-06 Metodos de reducao da toxicidade de 5-fluoracil com nucleosidos pirimidicos acilados PT1491201E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/472,210 US5968914A (en) 1987-10-28 1995-06-07 Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides

Publications (1)

Publication Number Publication Date
PT1491201E true PT1491201E (pt) 2006-08-31

Family

ID=23874595

Family Applications (1)

Application Number Title Priority Date Filing Date
PT04023557T PT1491201E (pt) 1995-06-07 1996-06-06 Metodos de reducao da toxicidade de 5-fluoracil com nucleosidos pirimidicos acilados

Country Status (14)

Country Link
US (2) US5968914A (pt)
EP (2) EP1491201B1 (pt)
JP (3) JPH10511689A (pt)
KR (1) KR19990022804A (pt)
CN (1) CN1192149A (pt)
AT (1) ATE320813T1 (pt)
AU (1) AU724805B2 (pt)
CA (1) CA2223640A1 (pt)
DE (1) DE69635941T2 (pt)
DK (1) DK1491201T3 (pt)
ES (1) ES2257721T3 (pt)
HK (1) HK1072897A1 (pt)
PT (1) PT1491201E (pt)
WO (1) WO1996040165A1 (pt)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7173017B1 (en) * 1987-10-28 2007-02-06 Wellstat Therapeutics Corporation Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
US7776838B1 (en) * 1987-10-28 2010-08-17 Wellstat Therapeutics Corporation Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
CA2213385A1 (en) * 1997-08-20 1999-02-20 Eng-Hong Lee Method of protecting against coccidiosis infections in poultry
AU8388198A (en) * 1997-08-21 1999-03-08 Basf Aktiengesellschaft Use of uridine to counter 5-fluorouracil toxicity
US6136339A (en) * 1998-08-21 2000-10-24 Gardiner; Paul T. Food supplements and methods comprising lipoic acid and creatine
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US7915233B1 (en) 1998-08-31 2011-03-29 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
US7807654B2 (en) 1998-08-31 2010-10-05 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
PT1171137E (pt) 1999-02-23 2008-03-17 Univ California Utilização de triacetiluridina para o tratamento de perturbações mitocondriais
US6875751B2 (en) * 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
AU2001278804A1 (en) * 2000-08-09 2002-02-18 Kolon Industries, Inc. 5'-deoxy-n-(substituted oxycarbonyl)-5-fluorocytosine and derivatives thereof, method of preparing same, and anticancer composition comprising same as active ingredients
US6613753B2 (en) * 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
AU2002306551A1 (en) * 2001-03-01 2002-09-19 Eli Lilly And Company Tumor treatement with a combination of a substrate of mrp5 and modulators of mrp5
DE10110355A1 (de) * 2001-03-03 2002-09-12 Ulrich Walker Bekämpfung von Nebenwirkungen
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
WO2002089772A1 (en) * 2001-05-09 2002-11-14 Inex Pharmaceuticals Corporation Anti-angiogenic therapy using liposome-encapsulated chemotherapeutic agents
SE521676C2 (sv) * 2002-01-02 2003-11-25 Dilafor Ab Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
US6998391B2 (en) * 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
US20030147813A1 (en) * 2002-02-07 2003-08-07 John Lyons Method for treating chronic myelogenous leukemia
EP1352910A1 (en) * 2002-04-10 2003-10-15 Grünenthal GmbH New analogs of nitrobenzylthioinosine
US6982253B2 (en) * 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
AU2003286836A1 (en) * 2002-10-31 2004-06-07 Supergen, Inc. Pharmaceutical formulations targeting specific regions of the gastrointestinal tract
WO2004104022A2 (en) * 2003-05-16 2004-12-02 The General Hospital Corporation Compositions comprising pathogen elicited epithelial chemoattractant (eicosanoid hepoxilin a3), inhibitors thereof and methods of use thereof
US20050037992A1 (en) * 2003-07-22 2005-02-17 John Lyons Composition and method for treating neurological disorders
US20050059682A1 (en) * 2003-09-12 2005-03-17 Supergen, Inc., A Delaware Corporation Compositions and methods for treatment of cancer
RS52217B (en) * 2004-04-29 2012-10-31 Taiho Pharmaceutical Co. Ltd. PROCEDURE FOR REDUCING GASTROINTESTINAL TOXICITY AFTER TEGAFUR ADMINISTRATION
US20080214606A1 (en) * 2004-06-18 2008-09-04 The Government of the United States of America as represented by The Secretary of the Dept. of ..... Methods for the Identification and Use of Compounds Suitable for the Treatment of Drug Resistant Cancer Cells
US20060024376A1 (en) * 2004-07-30 2006-02-02 The University Of Chicago Methods and compositions for reducing toxicity associated with leflunomide treatment
US20080255168A1 (en) * 2004-12-03 2008-10-16 Adherex Technologies, Inc. Methods for administering dpd inhibitors in combination with 5-fu and 5-fu prodrugs
US20060128653A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
US20060128654A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
US7250416B2 (en) * 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
US20070117776A1 (en) * 2005-11-04 2007-05-24 John Lyons Low Dose Therapy Of DNA Methylation Inhibitors
US20070105792A1 (en) * 2005-11-04 2007-05-10 Dimartino Jorge F Administration Of DNA Methylation Inhibitors For Treating Epigenetic Diseases
MX2008008076A (es) * 2005-12-22 2008-11-28 Conjuchem Biotechnologies Inc Procesos para la produccion de conjugados preformados de albumina y un agente terapeutico.
DE602007012904D1 (de) 2006-06-27 2011-04-14 Cbt Dev Lim Neue 2',3'-methylidenacetyladenosine prodrugs zur
JP2009541437A (ja) 2006-06-27 2009-11-26 ビオヴィトルム・アクチボラゲット（プブリクト） 治療用化合物
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain vehicles, installations and methods
CA2713288A1 (en) * 2008-02-11 2009-08-20 The Government Of The United States Of America As Represented By The Sec Retary Of Department Of Health And Human Services Compounds with mdr1-inverse activity
EP2265274B1 (en) 2008-03-03 2018-11-21 Tosk, Inc. Methotrexate adjuvants to reduce toxicity and methods for using the same
CA2750891C (en) 2008-12-22 2018-08-28 Board Of Trustees Of The University Of Illinois Compositions comprising decitabine and tetrahydrouridine and uses thereof
US9265785B2 (en) 2008-12-22 2016-02-23 The Board Of Trustees Of The University Of Illinois Compositions comprising decitabine and tetrahydrouridine and uses thereof
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
JO3262B1 (ar) * 2009-04-06 2018-09-16 Otsuka Pharma Co Ltd توليفة من ديسيتابين مع مثبط سيتيدين دي أميناز واستخدامها في علاج السرطان
WO2010118006A1 (en) * 2009-04-06 2010-10-14 Eisai Inc. (2 ' -deoxy-ribofuranosyl) -1,3,4, 7-tetrahydro- (1,3) iazepin-2-0ne derivatives for treating cancer
JP5684787B2 (ja) * 2009-04-06 2015-03-18 大塚製薬株式会社 シチジンベースの抗新生物薬とシチジンデアミナーゼ阻害薬との組合せ、および癌の治療におけるその使用
US8617540B2 (en) * 2009-04-15 2013-12-31 Fox Chase Cancer Center Combinational chemotherapy treatment
KR20120040184A (ko) 2009-07-15 2012-04-26 아사히 가라스 가부시키가이샤 적층체의 제조 방법 및 적층체
EP2348131A1 (en) 2010-01-22 2011-07-27 Institut Curie Low levels of cytidine deaminase as a marker for genetic predisposition to develop cancer
CN102775458B (zh) * 2011-05-09 2015-11-25 中国人民解放军军事医学科学院毒物药物研究所 β-D-(2’R)-2’-脱氧—2’-氟-2’-C-甲基胞苷衍生物的制备及用途
CN103945902B (zh) 2011-08-30 2018-07-20 阿斯泰克斯制药公司 地西他滨衍生物制剂
BR102013022567B1 (pt) * 2013-09-03 2021-09-21 Uniao Brasileira De Educacão E Assistência Uso de 6-hidroxi-2-piridonas e seus derivados na preparação de uma composição farmacêutica que atue pela inibição da enzima uridina fosforilase humana
CN104496972A (zh) * 2014-12-04 2015-04-08 浙江大学 一种新型替加氟药物共晶及其制备方法
CA2978521A1 (en) * 2015-05-29 2016-12-08 National Yang-Ming University Nucleoside agents for the reduction of the deleterious activity of extended nucleotide repeat containing genes
AU2016287585B2 (en) 2015-07-02 2020-12-17 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
EP3452044A4 (en) * 2016-06-28 2020-04-22 Cellix Bio Private Limited COMPOSITIONS AND METHODS FOR TREATING CANCER
JP2020529409A (ja) 2017-08-03 2020-10-08 大塚製薬株式会社 薬物化合物およびその精製方法
WO2020036974A1 (en) * 2018-08-14 2020-02-20 Tosk, Inc. Methods and compositions for reducing radiation induced toxicity
CN112789048A (zh) * 2018-08-14 2021-05-11 托斯克公司 用于治疗粘膜炎的方法和组合物
WO2020226889A1 (en) * 2019-05-07 2020-11-12 Wellstat Therapeutics Corporation Formulations of uridine triacetate in triacetin
US11446303B2 (en) 2019-06-21 2022-09-20 Tosk, Inc. Uridine phosphorylase (UPase) inhibitors for treatment of liver conditions
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
MX2022014094A (es) * 2020-05-19 2022-12-08 Cellix Bio Private Ltd Formulaciones farmaceuticas y sus preparaciones para el tratamiento del cancer.
WO2022056428A1 (en) * 2020-09-14 2022-03-17 Wellstat Therapeutics Corporation 2',3'-diacetyluridine substituted with acetoacetyl at the 5' position
WO2022226312A1 (en) * 2021-04-22 2022-10-27 Clear Creek Bio, Inc. Combination nucleotide pool depletion for treatment of viral infections and cancers
CN113332305B (zh) * 2021-06-03 2022-08-16 中国医学科学院医药生物技术研究所 胞苷类化合物的脂质组合物
CN113336816B (zh) * 2021-06-03 2022-05-17 中国医学科学院医药生物技术研究所 胞苷类化合物及其抗肿瘤用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1297398A (pt) * 1969-08-06 1972-11-22
US4017606A (en) * 1973-10-04 1977-04-12 The Upjohn Company Organic compounds and process
GB1473148A (pt) * 1974-09-16 1977-05-11
DE3100478A1 (de) * 1981-01-09 1982-08-12 Dr. Thilo & Co GmbH, 8021 Sauerlach 5'ester von pyrimidinnucleosiden mit antiviraler wirksamkeit, verfahren zur herstellung und daraus hergestellte arzneimittel
DE3481191D1 (de) * 1983-07-20 1990-03-08 Teijin Ltd Antineoplastisches mittel.
JPS60174797A (ja) * 1984-02-21 1985-09-09 Funai Corp Ν−アロイルチミジン誘導体ならびに抗腫瘍活性物質の毒性低下剤
US5736531A (en) * 1987-10-28 1998-04-07 Pro-Neuron, Inc. Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
AU2789989A (en) * 1987-10-28 1989-05-23 Pro-Neuron, Inc. Acylated uridine and cytidine and uses thereof
EP0355131B1 (en) * 1987-10-28 1996-09-04 Pro-Neuron, Inc. Acyl deoxyribonucleoside derivatives and uses thereof
US4874602A (en) * 1988-02-22 1989-10-17 Paul Calabresi Reduction of the severity 3'-azido-3'-deoxythymidine-induced anemia using benzylacyclouridine
US5077280A (en) * 1988-04-12 1991-12-31 Brown University Research Foundation Treatment of viral infections
US4950466A (en) * 1988-06-22 1990-08-21 Paul Calabresi Reduction of the severity of 3'-azido-3'-deoxythymidine-induced anemia using a combination of benzylacyclouridine and dipyridamole
IL93164A0 (en) * 1989-01-24 1990-11-05 Gensia Pharma Purine nucleosides and their medical use
US5132291A (en) * 1989-01-24 1992-07-21 Gensia Pharmaceuticals, Inc. Antivirals and methods for increasing the antiviral activity of azt
US5141943A (en) * 1990-04-12 1992-08-25 Brown University Research Foundation 5-benzyl barbiturate derivatives
DK0594667T3 (da) * 1991-07-05 2001-11-12 Pro Neuron Inc Behandling af kemoterapeutiske og antivirale, aktive stoffers toksiske virkning med acylerede pyrimidinnucleosider
WO1994026761A1 (en) * 1993-05-14 1994-11-24 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides

Also Published As

Publication number Publication date
US6344447B2 (en) 2002-02-05
HK1072897A1 (en) 2005-09-16
DK1491201T3 (da) 2006-07-31
ES2257721T3 (es) 2006-08-01
AU6111496A (en) 1996-12-30
KR19990022804A (ko) 1999-03-25
EP0831849A1 (en) 1998-04-01
EP0831849A4 (en) 2003-03-26
CA2223640A1 (en) 1996-12-19
ATE320813T1 (de) 2006-04-15
EP1491201B1 (en) 2006-03-22
JP2003201240A (ja) 2003-07-18
JPH10511689A (ja) 1998-11-10
DE69635941T2 (de) 2006-11-23
EP1491201A1 (en) 2004-12-29
JP2009167213A (ja) 2009-07-30
US20010025032A1 (en) 2001-09-27
AU724805B2 (en) 2000-09-28
CN1192149A (zh) 1998-09-02
DE69635941D1 (de) 2006-05-11
US5968914A (en) 1999-10-19
WO1996040165A1 (en) 1996-12-19

Similar Documents

Publication Publication Date Title
PT1491201E (pt) Metodos de reducao da toxicidade de 5-fluoracil com nucleosidos pirimidicos acilados
ATE314077T1 (de) 5-fluoro-2',3'-ungesättigte pyrimidinnucleoside
CA2301723A1 (en) Butyrate derivatives in the treatment of fibromyalgia and chronic fatigue syndrome
DE69703298D1 (de) Propargylethoxyamino nucleotide
AU7779994A (en) Stabilized oligonucleotides and their use
AU4134893A (en) 2'-deoxy-2',2'-difluoro(4-substituted pyrimidine) nucleosides having anti-viral and anti-cancer activity and intermediates
AU1966899A (en) Implant for implantation in the tongue
IT1273751B (it) Derivati azaciclici
KR900700110A (ko) 선암 치료용 전사효소 저해제
CA2033447A1 (en) Synergistic combination for treating herpes infections
AU9009391A (en) Antiherpes compositions and method of use
BG102342A (en) Optical active derivative of phenylpyrimidine as an anlgesics
IL92587A0 (en) 2',3'-dideoxypurine nucleoside/purine nucleoside phosphorylase inhibitor combination therapy and composition
RO118210B1 (ro) Metodă de inhibare a activităţii adenilosuccinat sintetazei în celulele deficitare în metiltioadenozinfosforilază
AU7881398A (en) Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
NO983402L (no) Nukeosidanaloger i kombinasjonsterapi av herpes simplex infeksjoner
DE69017917D1 (de) Schau- oder verkaufsregal zur anwendung in regalsystemen.
ZA9610073B (en) Method of using beta-interferons to treat restenosis
ATE186732T1 (de) (e)-2'-deoxy-2'-(fluormethylen)cytidin-monohydr t
ATE209060T1 (de) Ski
MX9801515A (es) Preparado de combinacion para la aplicacion en la demencia.
ATE282375T1 (de) Stent-katheter-anordnung
ITCA950008A0 (it) Impiego di combinaqzioni di analoghi di nucleosidi nella terapia delleinfezioni dell'aids.
TR199600677A1 (xx) Kenetli sac kapı sistemi.
MX9709749A (es) Metodo para reducir la toxicidad de agentes quimioterapeuticos y antivirales con nucleosidos de pirimidina acilados.